ATE119040T1 - Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. - Google Patents
Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.Info
- Publication number
- ATE119040T1 ATE119040T1 AT90114993T AT90114993T ATE119040T1 AT E119040 T1 ATE119040 T1 AT E119040T1 AT 90114993 T AT90114993 T AT 90114993T AT 90114993 T AT90114993 T AT 90114993T AT E119040 T1 ATE119040 T1 AT E119040T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cholecystokin
- antagonists
- central
- psychiatric diseases
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000000049 anti-anxiety effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38966589A | 1989-08-04 | 1989-08-04 | |
US42189689A | 1989-10-16 | 1989-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE119040T1 true ATE119040T1 (de) | 1995-03-15 |
Family
ID=27012795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90114993T ATE119040T1 (de) | 1989-08-04 | 1990-08-03 | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5550126A (de) |
EP (2) | EP0411668B2 (de) |
JP (1) | JPH0374328A (de) |
AT (1) | ATE119040T1 (de) |
CY (1) | CY1983A (de) |
DE (1) | DE69017302T3 (de) |
DK (1) | DK0411668T4 (de) |
HK (1) | HK8197A (de) |
LV (1) | LV11431B (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0374328A (ja) * | 1989-08-04 | 1991-03-28 | Warner Lambert Co | 薬学的活性を有する中枢コレシストキニン拮抗剤 |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5399565A (en) * | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
US5206238A (en) * | 1990-11-13 | 1993-04-27 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5220018A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5218115A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5220017A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5185331A (en) * | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
US5206237A (en) * | 1991-05-14 | 1993-04-27 | Merck & Co., Inc. | Benzodiazepine analogs |
EP0518484A3 (en) * | 1991-05-14 | 1993-03-17 | Merck & Co. Inc. | 1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders |
US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
WO1992021348A1 (en) * | 1991-06-03 | 1992-12-10 | Merck Sharp & Dohme Limited | Pharmaceutical formulations of a benzodiazepine |
US5177071A (en) * | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
WO1993012791A1 (en) * | 1991-12-20 | 1993-07-08 | Merck Sharp & Dohme Limited | Central cholecystokinin antagonists having pharmaceutical activity |
IT1263116B (it) * | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
JP3179493B2 (ja) * | 1992-04-22 | 2001-06-25 | 日本電産コパル株式会社 | アブソリュートエンコーダ |
US5360802A (en) * | 1992-05-11 | 1994-11-01 | Merck Sharpe & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5378838A (en) * | 1993-01-13 | 1995-01-03 | Merck & Co., Inc. | Benzodiazepine cholecystokinin antagonists |
US5852010A (en) * | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998000406A1 (en) * | 1996-07-02 | 1998-01-08 | Merck & Co., Inc. | Method for the treatment of preterm labor |
US5929071A (en) * | 1996-07-02 | 1999-07-27 | Merck & Co., Inc. | Method for the treatment of preterm labor |
US6194459B1 (en) | 1997-08-19 | 2001-02-27 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
EP1313426A4 (de) * | 1998-12-24 | 2003-05-28 | Bristol Myers Squibb Pharma Co | Succinoylaminobenzodiazepine als inhibitoren der a-beta proteinproduktion |
US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
AU5588400A (en) | 1999-05-26 | 2000-12-18 | Du Pont Pharmaceuticals Company | 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors |
US6960576B2 (en) * | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
WO2001027108A1 (en) | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
WO2001060826A2 (en) | 2000-02-17 | 2001-08-23 | Bristol-Myers Squibb Pharma Company | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
JP2003535046A (ja) * | 2000-04-03 | 2003-11-25 | デュポン ファーマシューティカルズ カンパニー | Aβタンパク質産生の阻害剤としての環状ラクタム |
BR0110051A (pt) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer |
CA2404273A1 (en) * | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
US20100009966A1 (en) * | 2001-04-11 | 2010-01-14 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of abeta protein production |
AU2001261728A1 (en) * | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
EP1268450A1 (de) | 2000-06-01 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Durch bernsteinsäurediamid substituierte lactamverbindungen als a-beta-protein-produktionsinhibitoren |
US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
US20030139396A1 (en) * | 2002-01-22 | 2003-07-24 | Karen Gibson | Method of treatment |
US20040167146A1 (en) * | 2002-01-22 | 2004-08-26 | Karen Jackson | Method of treatment |
US6713470B2 (en) * | 2002-01-22 | 2004-03-30 | Ml Laboratories Plc | Method of treatment |
US20040043990A1 (en) * | 2002-04-09 | 2004-03-04 | Karen Jackson | Method of treatment |
KR101155335B1 (ko) * | 2005-01-07 | 2012-06-11 | 엘지전자 주식회사 | 이동통신 단말기의 멀티미디어 메시지 동작방법 |
KR20150081370A (ko) | 2006-07-10 | 2015-07-13 | 파이온 유케이 리미티드 | 속효형 벤조디아제핀 염 및 이의 중합체 형태 |
MX2009011923A (es) * | 2007-05-10 | 2009-11-18 | Amr Technology Inc | Tetrahidrobenzo-1,4-diazepinas aril- y heteroaril-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina. |
EP2450039A1 (de) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosierschema zur Sedierung mit CNS 7056 (Remimazolam) |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2705039B1 (de) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomainhemmer und ihre verwendung |
EP2721031B1 (de) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomainhemmer und ihre verwendungen |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
EP3071206B1 (de) | 2013-11-22 | 2021-02-17 | CL Biosciences LLC | Gastrin antagonisten (zb yf476, netazepid) zur behandlung und vorbeugung von osteoporosis |
DK3157928T3 (da) | 2014-06-20 | 2019-05-20 | Constellation Pharmaceuticals Inc | Krystallinske former af 2-((4s)-6-(4-chlorphenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamid |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE57892B1 (en) * | 1984-06-25 | 1993-05-05 | Rotta Research Lab | Glutamic and aspartic acid derivatives |
CA1332410C (en) * | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Benzodiazepine analogs |
US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
IT1215169B (it) * | 1985-12-17 | 1990-01-31 | Rotta Research Lab | Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione |
IT1217123B (it) * | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
JPH0374328A (ja) * | 1989-08-04 | 1991-03-28 | Warner Lambert Co | 薬学的活性を有する中枢コレシストキニン拮抗剤 |
US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
-
1990
- 1990-08-03 JP JP2205335A patent/JPH0374328A/ja active Pending
- 1990-08-03 EP EP90114993A patent/EP0411668B2/de not_active Expired - Lifetime
- 1990-08-03 DE DE69017302T patent/DE69017302T3/de not_active Expired - Fee Related
- 1990-08-03 DK DK90114993T patent/DK0411668T4/da active
- 1990-08-03 EP EP94106046A patent/EP0727215A3/de not_active Withdrawn
- 1990-08-03 AT AT90114993T patent/ATE119040T1/de not_active IP Right Cessation
-
1995
- 1995-01-30 US US08/380,467 patent/US5550126A/en not_active Expired - Fee Related
-
1996
- 1996-02-05 LV LVP-96-32A patent/LV11431B/en unknown
-
1997
- 1997-01-16 HK HK8197A patent/HK8197A/xx not_active IP Right Cessation
- 1997-09-05 CY CY198397A patent/CY1983A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69017302T3 (de) | 1999-08-05 |
US5550126A (en) | 1996-08-27 |
DK0411668T3 (da) | 1995-03-27 |
EP0727215A3 (de) | 1996-11-06 |
EP0411668B2 (de) | 1998-11-11 |
HK8197A (en) | 1997-01-24 |
EP0411668B1 (de) | 1995-03-01 |
LV11431B (en) | 1996-12-20 |
LV11431A (lv) | 1996-08-20 |
EP0411668A3 (en) | 1992-01-29 |
CY1983A (en) | 1997-09-05 |
EP0411668A2 (de) | 1991-02-06 |
DK0411668T4 (da) | 1999-08-09 |
EP0727215A2 (de) | 1996-08-21 |
DE69017302D1 (de) | 1995-04-06 |
JPH0374328A (ja) | 1991-03-28 |
DE69017302T2 (de) | 1995-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE119040T1 (de) | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. | |
ATE398618T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten | |
ATE348829T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen | |
BR9407910A (pt) | Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto | |
DE69112895D1 (de) | Pharmazeutische Verbindungen. | |
FI960727A (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
DE3855113D1 (de) | Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht | |
ES2147616T3 (es) | Derivados de piperidina con actividad antagonista del paf. | |
CA2163118A1 (en) | Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use | |
DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
DE3887068D1 (de) | 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen. | |
DK0391185T3 (da) | 1,8-Naphthyridiner | |
ATE141796T1 (de) | 2',5'-oligoadenylat-derivate zur verwendung als heilmittel | |
DE3380923D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen. | |
DE59003418D1 (de) | Verfahren zur Herstellung von reinen C4-C7-tert.-Alkenen. | |
DE3850044D1 (de) | Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten. | |
SE8802323D0 (sv) | 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it | |
ATE402178T1 (de) | Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten | |
DE59003806D1 (de) | Zubereitung eines salzes von oxypurinol in oraler form zur behandlung von hyperuricämie. | |
BR9810331A (pt) | Sal de adição de ácido maléico de 2-etil-5-(1-metil-1,2,5,6-tetraidro-3-piridil-2h-tetrazol ; composições farmacêuticas contendo o referido sal; método para sua preparação e a utilização do mesmo em tratamento de doenças | |
DE59405654D1 (de) | T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen | |
ATE97444T1 (de) | Methode und verbindungen zur herstellung von acsf und acsf-antagonisten. | |
IT8919204A0 (it) | Composizione per la prevenzione e la cura di parodontopatte. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |